Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Earnings Bleak, BioMarin Scrambles To In-License

This article was originally published in The Pink Sheet Daily

Executive Summary

Kuvan-launch mistakes and the Riquent fizzle take their toll, as company shops for workable assets.

You may also be interested in...



Licensing PARP Inhibitor A Win For BioMarin, Medivation

BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.

Riquent Trial Fails; Is This La Jolla’s Last Gasp?

Data monitoring board says continuing ASPEN trial is “futile” after first interim look at BioMarin-licensed Riquent trial for treatment of lupus nephritis.

BioMarin Tightens Loose Rivets On Bridge To Wider PKU Market

Firm corrects bad numbers for Kuvan new-patient starts ahead of early results with second – and maybe bigger – market player, PEG-PAL

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel